Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats

Cardiovascular Research

Volumn 104, Issue 1, 2014, Pages 5-14

  Saito, Shotaro ^a   Teshima, Yasushi ^a   Fukui, Akira ^a   Kondo, Hidekazu ^a   Nishio, Satoru ^a   Nakagawa, Mikiko ^a   Saikawa, Tetsunori ^a   Takahashi, Naohiko ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Diabetes mellitus; Glucose fluctuation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLUCOSE; LONG ACTING INSULIN; MALONALDEHYDE; PIG INSULIN; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOREDOXIN INTERACTING PROTEIN; ACTIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CARRIER PROTEIN; CASP3 PROTEIN, RAT; GLUCOSE BLOOD LEVEL; SMOOTH MUSCLE ACTIN, RAT; TXNIP PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPH; ENZYME BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBROSIS; HEART WEIGHT; INSULIN BLOOD LEVEL; INSULIN TREATMENT; MALE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; UPREGULATION; WEIGHT CHANGE; WEIGHT GAIN; ACTION POTENTIAL; ANIMAL; ATRIAL FIBRILLATION; BLOOD; CELL CULTURE; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REFRACTORY PERIOD; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TIME;

ACTINS; ACTION POTENTIALS; ANIMALS; APOPTOSIS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARRIER PROTEINS; CASPASE 3; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE III; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; FIBROSIS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MALONDIALDEHYDE; MYOCARDIUM; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SIGNAL TRANSDUCTION; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84913527715     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu176     Document Type: Article

References (49)

1. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on allcause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21:1167-1172
2. Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease?. The Framingham Study. Am Heart J 1991;121:586-590
3. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
4. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297
5. Dave KR, Tamariz J, Desai KM, Brand FJ, Liu A, Saul I, Bhattacharya SK, Pileggi A. Recurrent hypoglycemia exacerbates cerebral ischemic damage in streptozotocin-induced diabetic rats. Stroke 2011;42:1404-1411
6. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells. Diabetes 2003;52:2795-2804
7. Benjamin EJ, Wolf PA, DAgostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98: 946-952
8. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
9. Kato T, Yamashita T, Sekiguchi A, Sagara K, Takamura M, Takata S, Kaneko S, Aizawa T, Fu LT. What are arrhythmogenic substrates in Diabetic rat atria?. J Cardiovasc Electrophysiol 2006;17:890-894
10. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977;60:884-899
11. van Hoeven KH, Factor SM.Acomparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848-855
12. Dallak MM, Mikhailidis DP, Haidara MA, Bin-Jaliah IM, Tork OM, Rateb MA, Yassin HZ, Al-Refaie ZA, Ibrahim IM, Elawa SM, Rashed LA, Afifi NA. Oxidative stress as a common mediator for apoptosis induced-cardiac damage in Diabetic rats. Open Cardiovasc Med J 2008;2:70-78
13. Li J, Zhu H, Shen E, Wan L, Arnold JM, Peng T. Deficiency of rac1 blocksNADPHoxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 2010;59:2033-2042
14. Fukui A, Takahashi N, Nakada C, Masaki T, Kume O, Shinohara T, Teshima Y, Hara M, Saikawa T. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol 2013;6:402-409
15. Wakisaka O, Takahashi N, Shinohara T, Ooie T, Nakagawa M, Yonemochi H, Hara M, Shimada T, Saikawa T, Yoshimatsu H. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J Mol Cell Cardiol 2007;43:616-626
16. Kume O, Takahashi N, Wakisaka O, Nagano-Torigoe Y, Teshima Y, Nakagawa M, Yufu K, Hara M, Saikawa T, Yoshimatsu H. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011;8:278-285
17. Kohno H, Takahashi N, Shinohara T, Ooie T, Yufu K, Nakagawa M, Yonemochi H, Hara M, Saikawa T, Yoshimatsu H. Receptor-mediated suppression of cardiac heatshock protein 72 expression by testosterone in male rat heart. Endocrinology 2007; 148:3148-3155
18. Nishio S, Teshima Y, Takahashi N, Thuc LC, Saito S, Fukui A, Kume O, Fukunaga N, Hara M, Nakagawa M, Saikawa T. Activation of CaMKII as a key regulator of reactive oxygen species production in Diabetic rat heart. J Mol Cell Cardiol 2012;52:1103-1111
19. Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M, Aubier M, Mercadier JJ, Reed JC, Hatem SN. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34:1577-1586
20. Xu GJ, Gan TY, Tang BP, Chen ZH, Mahemuti A, Jiang T, Song JG, Guo X, Li YD, Miao HJ, Zhou XH, Zhang Y, Li JX. Accelerated fibrosis and apoptosis with ageing and in atrial fibrillation: Adaptive responses with maladaptive consequences. Exp Ther Med 2013;5: 723-729
21. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115: 3213-3223
22. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107: 1058-1070
23. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-1354
24. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
25. World CJ, Yamawaki H, Berk BC. Thioredoxin in the cardiovascular system. J Mol Med (Berl) 2006;84:997-1003
26. Fang S, Jin Y, Zheng H, Yan J, Cui Y, Bi H, Jia H, Zhang H, Wang Y, Na L, Gao X, Zhou H. High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway. Mol Cell Biochem 2011;347:175-182
27. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004;279:30369-30374
28. Wang Y, De Keulenaer GW, Lee RT. Vitamin D3-up-regulated protein-1 is a stressresponsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 2002;277:26496-26500
29. Xiang G, Seki T, Schuster MD, Witkowski P, Boyle AJ, See F, Martens TP, Kocher A, Sondermeijer H, Krum H, Itescu S. Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem 2005;280:39394-39402
30. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501
31. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011;51:1289-1301
32. Haudek SB, Taffet GE, Schneider MD, Mann DL. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest 2007;117:2692-2701
33. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNF-A-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120:649-661
34. Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, Feghali-Bostwick C, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial reactive oxygen species regulate transforming growth factor-b signaling. J Biol Chem 2013;288:770-777
35. Stambler BS, Fenelon G, Shepard RK, Clemo HF, Guiraudon CM. Characterization of sustained atrial tachycardia in Dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 2003;14:499-507
36. Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 2014;114:1483-1499
37. Kakkar R, Lee RT. Intramyocardial fibroblast myocyte communication. Circ Res 2010; 106:47-57
38. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 2011;89:744-753
39. Shimoni Y, Firek L, Severson D, GilesW. Short-Term diabetes alters K+ currents in rat ventricular myocytes. Circ Res 1994;74:620-628
40. Watanabe M, Yokoshiki H, Mitsuyama H, Mizukami K, Ono T, Tsutsui H. Conduction and refractory disorders in the diabetic atrium. Am J Physiol Heart Circ Physiol 2012;303: H86-H95
41. Otake H, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in Diabetic heart. Int Heart J 2009;50:627-641
42. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, Van Wagoner DR. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001;89:E32-E38
43. Galaris D, Korantzopoulos P. On the molecular mechanism of metmyoglobin-catalyzed reduction of hydrogen peroxide by ascorbate. Free Radic Biol Med 1997;22:657-667
44. Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, Donahue JK. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 2012;125:216-225
45. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002;54:361-379
46. Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 2012;33: 1870-1877
47. Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation 2012;126:2353-2362
48. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47:693-700
49. Group UHS. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-1147